Of 12 patients (colorectal, n = 6; appendiceal cancer, n = 2; NSCLC, n = 2; duodenal, n = 1; breast cancer, n = 1) who had KRAS G12 or G13 mutations in the tumor tissue did not have these mutations in their cfDNA. This evidence concerns the gene KRAS and non-small cell lung carcinoma.